Schedule 13G ownership disclosure
BIOXCEL THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 09075P105
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Oaktree Fund Advisors, LLC
Shares: 51,429 · Class: 0.83%
- Oaktree Capital Management LP
Shares: 118,801 · Class: 1.91%
- Oaktree Capital Holdings, LLC
Shares: 170,230 · Class: 2.73%
- Oaktree Capital Group Holdings GP, LLC
Shares: 170,230 · Class: 2.73%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001140361-25-019286
- Form type
- SCHEDULE 13G/A
- Filer
- BioXcel Therapeutics, Inc.
- CIK
- CIK 1720893
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership